Global Companion Diagnostics Market Insights 

Companion Diagnostic refers to therapeutic devices that are used to diagnose the response of treatment in the patients as well as in vitro gadgets. These devices provide essential information that is required for the effective and safe use of corresponding medicine or biological products. The outcome as in the diagnostic report helps a health care professional to determine if the benefits of a particular therapeutic product will compensate with some potentially serious side effects or risks.

Acknowledging the huge prominence, the market is garnering currently; Market Research Future (MRFR) in its recently published study report asserts that the global companion diagnostics market size is projected to grow exponentially by 2030,, registering a striking double-digit CAGR of 11.90% throughout the forecast period (2022 – 2030). The burgeoning healthcare sector is a key factor propelling market growth.

Similarly, companion diagnostics is also used in the drug development process by determining companion biomarker that helps predict potential response of toxicity. During the past few years, with the advancements in biotechnology, companion diagnostics have evolved dramatically.  Additionally, the growing prevalence of chronic diseases such as cancer and HIV has helped companion diagnostics to garner huge prominence. This, as a result, has escalated the companion diagnostics market on the global platform.

Besides, other factors such as the growing population, urbanization coupled with the adoption of heady, inappropriate lifestyle foster the market growth contributing to the incidences of chronic diseases.  Moreover, continuous advancement in medical technology in both - for the diagnosis and the treatment of patients propel the market growth. Also, the spreading awareness among physicians and patients about the drug toxicity is providing impetus to the market growth.

On the other hand, skepticism of physicians towards the advancement efficacies of these devices is likely to restrict the market growth. In developing countries due to less awareness, companion diagnostics are not as much in practice as in developed countries, but the developing countries with huge population like India China have a vast potential to pull in the market share.

Whereas in developed countries, lack of skilled professionals and lack of awareness is hampering the growth of companion diagnostics market. Besides, logistic issues raised so as to develop companion diagnostics and drug together are posing challenges to the market growth. 

Global Companion Diagnostics Market – Segmentations

The MRFR analysis is segmented into four key dynamics for the convenience of understanding;

By Types           Comprises Monitoring Tests, and Theragnostic Tests among others.  

By End Users           : Hospital, Research Laboratories, and Medical Institutes among others.

By Applications        : Cardiovascular, Cancer Diseases, and Central Nervous Systems among others.

By Regions           :  North America, Europe, APAC and the Rest-of-the-World.

Global Companion Diagnostics Market – Geographical Analysis

North America market dominates the global companion diagnostics market outlook report with a significant market share. The market is further estimated to create a huge revenue pocket growing at a strong CAGR throughout the forecast period (2017-2023).

The European and Asia Pacific region accounts for the second and third largest market, respectively.  Among the various factors driving the market growth in the developed regions such as North America and Europe include high per capita healthcare expenses, substantial funding support from the public and private sector for RD activities, and a well-proliferated healthcare sector.

Whereas the companion diagnostics market in the Asia Pacific region is driven by the vast patient pool, unmet clinical needs, and the low-cost treatment procedures.  The APAC companion diagnostics market is expected to emerge as a promising market over the projected period.

Global Companion Diagnostics Market – Competitive Landscape

The companion diagnostics market appears to be fiercely competitive as well as fragmented due to the presence of many large and small-scale players accounting for a substantial market share. Market players try to gain a competitive advantage through strategic initiatives like partnership, acquisition, expansion, collaboration, and product technology launch. They invest heavily in the RD to develop a technology that is completely on a different level compared to their competition. 

Key Players:

Fervent players leading the global companion diagnostics market include Agilent Technologies (U.S.), Abbott (U.S.), ARUP Laboratories (U.S.), Myriad Genetics Inc. (U.S.), F. Hoffmann-La Roche AG. (Germany), Thermo Fisher Scientific Inc. (U.S.), and Qiagen N.V. (Germany).

Industry/Innovation/Related News:

November 27, 2018 – Invivoscribe (US), an industry pioneer in developing and manufacturing diagnostic products announced the submission of the LeukoStrat® CDx FLT3 Mutation Assay to both the US FDA and the Japan PMDA (Pharmaceuticals and Medical Devices Agency) as the companion diagnostic for quizartinib.

LeukoStrat is developed in partnership with Daiichi Sankyo as the companion diagnostic that bridges to the global phase 3 QuANTUM-R clinical trial (United States, Europe, and Asia excluding Japan).

 October 09, 2018 -- Myriad Genetics, Inc. (US), a global leader in personalized medicine, announced signing of a commercialization plan with Pfizer Inc. (US), a pharmaceutical corporation that is under an existing companion diagnostic agreement, in which Myriad is pursuing U.S. Food and Drug Administration (FDA) approval for its BRACAnalysis CDx® to be used as a companion diagnostic with Pfizer’s investigational PARP (poly ADP ribose polymerase) inhibitor, talazoparib.


About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: [email protected]